Potential Upside in Obesity Treatment as Higher Dose Efficacy Data Expected to Boost Competitive Profile
Viking Therapeutics (VKTX) is gearing up for a pivotal moment as it prepares to unveil data for its oral VK2735 candidate at the ObesityWeek conference, held from November 3-6. This data could significantly shape investor sentiment, as the company has positioned VK2735 as a potential game-changer in obesity treatment. With prior Phase 1 results showing encouraging weight-loss outcomes at a 40mg dose, expectations are high for even better results at higher doses of 60mg, 80mg, and 100mg.
Key Results from Initial Trials
VK2735 has already demonstrated significant promise in Phase 1 trials, with topline data from the 40mg dose cohort revealing a 5.3% mean weight loss over 28 days, compared to just 2.1% in the placebo group. This resulted in a 3.3% placebo-adjusted weight loss, which was statistically significant (p=0.0006). Importantly, the tolerability profile was robust, with only about 25% of participants experiencing mild nausea and no reports of vomiting, suggesting a wide therapeutic window for higher doses.
As VKTX prepares to present data from the higher dose cohorts (60mg, 80mg, and 100mg), the stakes are high. Analysts expect the 60-100mg doses to show up to a 6% reduction in body weight over the same 28-day period. If these expectations are met or exceeded, VK2735 could position itself as a highly competitive player in the oral obesity treatment market, especially if the nausea incidence remains below 40%, as anticipated.
Market Outlook and Upside Potential
If the upcoming data meets expectations, VKTX could see a 35% upside in its stock price, driven by a 75% probability of success (POS) attributed to the results. Conversely, if the results fall short—either due to a lack of incremental weight loss or concerns around tolerability—the stock could face a downside of around 40%.
Despite this potential volatility, many investors are optimistic about VKTX’s future. The company’s dual approach—developing both oral and subcutaneous formulations of VK2735—provides flexibility and optionality for physicians, further increasing the drug’s commercial potential. VKTX’s strong performance in early trials and its robust pipeline suggest the company is well-positioned for future growth in the highly competitive obesity treatment market.
Long-Term Potential for VK2735
Oral agents are increasingly seen as the future of obesity treatment due to their convenience, lower manufacturing costs, and potential for combination therapies with other medications targeting comorbidities. VKTX is likely to pursue a manufacturing solution via a contract manufacturing organization (CMO) or form a partnership with a large pharmaceutical company to scale production. Such partnerships could also facilitate the introduction of VK2735 into new markets, including over-the-counter (OTC) channels.
A recent survey of primary care physicians (PCPs) who prescribe GLP-1 therapies indicated that approximately 50% of respondents would support the eventual availability of an oral obesity agent in OTC formats. This presents a significant commercial opportunity for VKTX, as it opens the door to partnerships with larger pharmaceutical companies seeking to expand their presence in the obesity treatment space.
Broader Pipeline: VK2809 and NASH
VKTX’s portfolio extends beyond VK2735, with the company also advancing its lead candidate, VK2809, for the treatment of non-alcoholic steatohepatitis (NASH). VK2809 is a thyroid hormone receptor (THR-β) agonist, and its Phase 2a results showed impressive liver fat reduction, similar to Madrigal Pharmaceuticals’ resmetirom. With the NASH market poised for significant growth in the coming years, VK2809 represents another strong revenue driver for VKTX. The company plans to begin a Phase 2b biopsy-confirmed trial for VK2809, which could pave the way for Phase 3 development.
If VK2809 achieves positive Phase 2b outcomes, VKTX’s market cap could be significantly undervalued compared to its peers, positioning it for a re-rating by investors. This provides an additional layer of asymmetric upside potential for the company.
Valuation and Price Target
VKTX’s current valuation reflects both the potential upside and risks associated with its pipeline. Analysts have set a 12- to 18-month price target of $138 per share, based on a discounted cash flow (DCF) valuation methodology. This assumes a weighted average cost of capital (WACC) of 11% and a residual growth rate of -1%, accounting for the expected patent expirations of VK2809 and VK2735.
Forecasts indicate that VK2809 could generate risk-adjusted global peak sales of approximately $1.6 billion by 2032, while VK2735 could reach an impressive $12.7 billion in global sales by 2040, assuming successful commercialization and market penetration. Analysts estimate an 80% probability of success (POS) for both VK2809 and VK2735, further supporting the company’s bullish outlook.
Conclusion
As VKTX prepares to present data on higher doses of VK2735 at ObesityWeek, the company finds itself at a critical juncture. The results from this data could provide a significant catalyst for the stock, with potential for substantial upside if the drug shows enhanced efficacy and manageable tolerability at higher doses. With a strong pipeline and a growing presence in two major therapeutic areas—obesity and NASH—VKTX appears well-positioned to capitalize on its innovative treatments and drive long-term value for investors.
You might like this article:China’s Stock Rally Loses Momentum as Stimulus Hopes Fade
